Achillion's 'Very Promising' Drug for Hepatitis C Viral hepatitis is the leading cause of liver cancer and the most common reason for a liver transplant, but few treatments exist. CEO Mike Kishbauch explains how Achillion is trying to change that. Wall Street is watching.